MultipleMS MS Progression GWAS supporting material: Severity Scores of MS patients from Sweden

Meta-data for n=2751 MS cases from Sweden (European ancestry) that passed sample quality control and had at least one disability measure were included in the analysis. All participants gave written informed consent in accordance with approval from the relevant local ethical committees or institutional review boards. Patients with MS were ascertained and diagnosed by a neurologist locally according to established criteria. Neurological disability was measured using the EDSS29, an ordinal scale which incorporates a range of neurological functions relevant to MS. EDSS was scored by neurologist assessment. For each individual, the last recorded EDSS was converted to an ARMSS score by ranking disability against participants with the same age (±2 years) from the same cohort. The file includes the following metadata: SUBJECT_ID: Anonymized participant identifiers CENTER: The research center where the data was collected CHIP: The genotyping chip used SEX: Participant's sex AGE: Participant's age RINT_ARMSS: The RINT-ARMSS score, a measure of MS disease severity ANCESTRY: Participant's ancestry

本分析纳入了来自瑞典（欧洲血统）的2751例多发性硬化（Multiple Sclerosis, MS）病例的元数据，所有病例均通过样本质量控制，且至少包含一项残疾评估指标。所有参与者均按照相关地方伦理委员会或机构审查委员会的批准要求签署了书面知情同意书。多发性硬化患者由当地神经科医师依据既定临床标准确诊并入组。神经功能残疾采用扩展残疾状态量表29（EDSS29）进行评估，该序数量表涵盖了与MS相关的多项神经功能维度，其评分由神经科医师通过临床评估完成。针对每名受试者，将其末次记录的EDSS评分，参照同队列中年龄偏差不超过±2岁的受试者的残疾水平进行排序，从而转换为ARMSS评分。本数据集包含以下元数据：SUBJECT_ID：匿名化受试者标识符；CENTER：数据采集的研究中心；CHIP：所用基因分型芯片；SEX：受试者性别；AGE：受试者年龄；RINT_ARMSS：RINT-ARMSS评分，用于衡量MS疾病严重程度；ANCESTRY：受试者血统。